AXAFA – AFNET 5 trial presented at EHRA Congress today

AF ablation with Apixaban or VKA is safe and may have a positive effect on cognitive function

Atrial fibrillation ablation with continuous Apixaban does not increase the risk of stroke or bleeding compared to vitamin K antagonists and may have a positive effect on cognitive function. These are the key findings from the investigator-initiated clinical trial AXAFA – AFNET 5. The results are presented at the EHRA congress in Barcelona, Spain, today [1, 2]. (Mehr in: Pressemitteilungen – idw – Informationsdienst Wissenschaft)